Sorin highlights its latest technologies in Cardiac Rhythm Managment at Cardiostim 2004 Download Documentation
The Sorin Group highlights its latest Cardiac Rhythm Management technologies at Cardiostim 2004
Nice, June 16th, 2004 – Sorin, Europe's largest cardiovascular medical devices group, is attending Cardiostim 2004, the 14th World Congress in Cardiac Electrophysiology and Cardiac Technologies, in Nice. Cardiostim is a major international meeting with more than 5,000 participants from 70 countries, and some 1,400 presentations and symposia. The Sorin Group is presenting two distinct product lines – ELA Medical and Sorin Biomedica CRM - at what is viewed as one of the most important venues in the world for technologies and therapies used to prevent and treat cardiac rhythm disorders.
"The growth in the CRM market is a cornerstone of our Group's profitable growth in the next few years. We are present at Cardiostim with a number of new products and technologies — some just introduced in Europe — that position us at the forefront of diagnostic and therapeutic fields" said Drago Cerchiari, the Chief Executive Officer of the Sorin Group.
Andre-Michel Ballester, President of Sorin Group's CRM Business Unit, added "I believe our product offering in CRM is really impressive and confirms Ela Medical's and Sorin's continuing commitment to work together with the medical community to enhance patients well being. We are also organizing at Cardiostim three main symposia where emerging clinical and therapeutic solutions for the most significant heart diseases will be discussed"
The CRM market
The world market of devices and technologies for the treatment of cardiac rhythm disorders is worth about 6,6 billions Euro and is poised to grow at more than 10% per year in the period between 2004 and 2008. Each year, 880.000 pacemakers are implanted in the world (325.000 in Europe) and about 180.000 ICDs (Implantable Defibrillators): 29.000 in Europe and 135.000 in the USA. The growth in this sector is fueled by the ageing of the population and new therapeutic indications, such as treatment of Heart Failure and Atrial Fibrillation.
The Sorin Group's main therapy solutions
The Sorin Group has a complete portfolio of advanced devices to treat a wide range of arrhythmia diseases.
SYMPHONY® is the last generation of pacemakers produced by ELA Medical; it introduces exclusive features for the treatment of bradycardia, enabling cardiologists to easily tailor the functions of pacemakers to the individual needs of each patient. The great versatility of these devices obviates the need for compromises that restrict treatment options. These devices use the new AAIsafeRTM stimulation mode* that eliminates some of the shortcomings of conventional pacing systems, as confirmed in numerous international clinical trials. It ensures patient safety and respects the heart's own physiology by stimulating the ventricle only when truly necessary, instead of competing with the heart's normal beating. The clinical results show that AAIsafeR preserves ventricular activity in case of paroxysmal AV block while maintaining ventricular pacing below 1% in 65% of patients. This new feature could become the gold standard in cardiac rhythm management and permit a significant reduction in hospitalizations for congestive heart failure, atrial fibrillation and other serious cardiac events.
The sleep apnea diagnosis function is one of the breakthrough technologies integrated in Talent 3 MSP, a device that is also intended to treat congestive heart failure with cardiac resynchronization therapy (CRT). Sleep apnea causes day-time sleepiness and increases the risk of hypertension and cardiovascular diseases. A high prevalence (57% of patients) of sleep apnea episodes is observed in patients implanted with a CRT pacemaker. Diagnosing the condition is of the utmost importance in heart failure patients.
ALTOÒ 2 ICD integrates a unique slow ventricular tachycardia (VT) management feature that enhances the patient's quality of life. Slow VTs are indeed treated without the side effects of delivering inappropriate shocks and programming constraints. Clinical data show that more than 25% of ICD patients present with unexpected slow VTs. The PARAD/PARAD+Ò algorithm automatically interprets the heart's rhythm and discriminates among different types of tachyarrhythmia.
The ALTOÒ 2 MSP*system is dedicated to the treatment of heart failure patients providing the CRT therapy while preventing sudden cardiac death, is a leading cause of death in heart failure patients. ALTO 2 MSP maintains the unique arrhytmia detection and discrimination features of ALTO2.
The BEST LIVING system (developed and produced by Sorin Biomedica CRM) is the only device capable of monitoring left ventricular function by measuring Peak Endocardial Acceleration (PEA). Numerous clinical studies have shown that the system is able of assessing every aspect of the heart's functionality and providing therapeutic solutions also for heart failure patients (LIVING CHF). The BEST LIVING system can monitor and optimize therapy effectiveness and has the unique ability to determine the best stimulation configuration as well as AV Delay and VV interval.
The NEWAY pacemaker family offers a new powerful diagnostics option which, starting from an immediate pacing system overview, analyses sequentially every significant event. The device features also a unique algorithm based on the Autonomic Nervous System assessment for tachy-arrhythmic episodes management. The product profile is completed by a patented solution for automatic and safe implantation procedure.
The Sorin Group (Reuters code: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm disorders, interventional cardiology and the treatment of chronic kidney disease. The companies of the Sorin Group are: Dideco, CarboMedics, COBE Cardiovascular, Stöckert, Mitroflow, ELA Medical, Sorin, Sorin Biomedica, Bellco and Soludia. The Sorin Group has about 4,800 employees working at facilities in more than 80 countries in every region of the world to serve over 5,000 public and private treatment centers.
* Under clinical evaluation in the U.S.
Media Communications: Federico Unnia